Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Anthera Pharmaceuticals Incex32_2.htm
EX-32.1 - EXHIBIT 32.1 - Anthera Pharmaceuticals Incex32_1.htm
EX-31.2 - EXHIBIT 31.2 - Anthera Pharmaceuticals Incex31_2.htm
EX-31.1 - EXHIBIT 31.1 - Anthera Pharmaceuticals Incex31_1.htm
EX-10.41 - EXHIBIT 10.41 - Anthera Pharmaceuticals Incex10_41.htm
EX-10.39 - EXHIBIT 10.39 - Anthera Pharmaceuticals Incex10_39.htm
EX-10.38 - EXHIBIT 10.38 - Anthera Pharmaceuticals Incex10_38.htm
EX-10.37 - EXHIBIT 10.37 - Anthera Pharmaceuticals Incex10_37.htm
EX-10.36 - EXHIBIT 10.36 - Anthera Pharmaceuticals Incex10_36.htm
EX-10.35 - EXHIBIT 10.35 - Anthera Pharmaceuticals Incex10_35.htm
10-K - Anthera Pharmaceuticals Inca22118010k.htm
 Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM



 
Anthera Pharmaceuticals, Inc.
Hayward, California

We hereby consent to the incorporation by reference in the Registration Statements on Form S--3 (No. 333-175095, No. 333-179043, No. 333-187771, No. 333-187780 and No. 333-210166) and Form S--8 (No. 333-165714, No. 333-168970, 333-172100, No. 333-180144, No. 333-186679 No. 333-196740 and No. 333-213956) of Anthera Pharmaceuticals, Inc. of our reports dated March 5, 2018, relating to the consolidated financial statements.  Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
 
 
/s/ BDO USA, LLP
 
San Francisco, California
March 5, 2018